PeptiDream Inc
TSE:4587

Watchlist Manager
PeptiDream Inc Logo
PeptiDream Inc
TSE:4587
Watchlist
Price: 1 665.5 JPY 3.03% Market Closed
Market Cap: 216.5B JPY

PeptiDream Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

PeptiDream Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
PeptiDream Inc
TSE:4587
Net Income (Common)
-ÂĄ5.8B
CAGR 3-Years
-85%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
3
3-D Matrix Ltd
TSE:7777
Net Income (Common)
-ÂĄ948.3m
CAGR 3-Years
16%
CAGR 5-Years
19%
CAGR 10-Years
6%
Healios KK
TSE:4593
Net Income (Common)
-ÂĄ6B
CAGR 3-Years
2%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Net Income (Common)
-ÂĄ701.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-5%
Takara Bio Inc
TSE:4974
Net Income (Common)
ÂĄ577m
CAGR 3-Years
-68%
CAGR 5-Years
-26%
CAGR 10-Years
-4%
C
Cuorips Inc
TSE:4894
Net Income (Common)
-ÂĄ644.3m
CAGR 3-Years
-20%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

PeptiDream Inc
Glance View

PeptiDream Inc., a biopharmaceutical powerhouse based in Japan, has carved out a formidable niche by leveraging its proprietary Peptide Discovery Platform System (PDPS) to revolutionize drug development. Founded in 2006 by a team of visionary scientists, the company has positioned itself at the cutting edge of peptide therapeutics. By using the PDPS, PeptiDream identifies and optimizes macrocyclic peptide candidates that have the potential to address a myriad of complex diseases with unmet medical needs. This platform enables the company to create highly specific peptide-based drugs that can modulate challenging targets previously deemed “undruggable” by conventional methods. For PeptiDream, innovation isn’t just a mission statement but an operational ethos that drives its strategic collaborations and partnerships across the pharmaceutical landscape. Revenue generation at PeptiDream is predominantly through multi-faceted strategic collaborations with leading global pharmaceutical companies. By partnering with industry titans, PeptiDream licenses access to its cutting-edge PDPS technology and collaborates on drug discovery and development projects. This collaborative approach allows the company to secure upfront payments, research funding, milestone payments, and potential royalties on the eventual sales of successfully commercialized drugs. By securing a steady stream of income through these partnerships, PeptiDream not only sustains its robust research and development initiatives but also fuels an innovation pipeline that positions it as a leader in the burgeoning field of peptide-based therapeutics.

Intrinsic Value
1 834.08 JPY
Undervaluation 9%
Intrinsic Value
Price

See Also

What is PeptiDream Inc's Net Income (Common)?
Net Income (Common)
-5.8B JPY

Based on the financial report for Sep 30, 2025, PeptiDream Inc's Net Income (Common) amounts to -5.8B JPY.

What is PeptiDream Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-85%

The average annual Net Income (Common) growth rates for PeptiDream Inc have been -85% over the past three years .

Back to Top